WNL Biomed Tech Pty Ltd unveiled its headquarters, R&D and production base at in the Smart Health Town in Torch Development Zone on June 30. With a wide range of product pipelines, WNL Biomed is expected to fill the gap in the therapeutic vaccine market and bring new treatment methods to cancer patients, said WNL Biomed chairman Liu Xiaosong.

WNL Biomed, founded by three senior doctors of immunology in 2018 and moved into the National Health Technology Park in June 2022, is specialized in the research and development of therapeutic vaccines and peptide drugs for malignant tumors, skin drug-resistant bacterial infections and other diseases. In the past three years, the company has formed partnerships with leading pharmaceutical companies engaged in new drug development and become an emerging new drug developer.

In recent years, with a focus on frontier drug R&D and innovation, Torch Development Zone has brought in a host of innovative drug developers including RabPharma, Frontier Gate Biotech, Findcure and Constimulus Bio.